Curex Clinical Gaps and Limitations: What They Miss

What Curex Offers in the GLP-1 Space

Curex operates as a direct-to-consumer telehealth platform prescribing GLP-1 receptor agonists for weight loss through a cash-pay model, bypassing traditional insurance channels. The service connects patients with licensed providers who evaluate eligibility and prescribe medications like semaglutide or tirzepatide.

This model has grown rapidly. The FDA approved semaglutide 2.4 mg (Wegovy) for chronic weight management in June 2021 based on the STEP 1 trial, which enrolled 1,961 adults and demonstrated 14.9% mean body weight reduction at 68 weeks versus 2.4% with placebo [1]. That trial success generated enormous consumer demand, and dozens of telehealth platforms now compete for patients willing to pay out of pocket.

But STEP 1 participants received far more than a prescription. They had structured dietary counseling (500 kcal/day deficit), 150 minutes per week of physical activity guidance, and 30 scheduled clinic visits over 68 weeks [1]. The gap between that protocol and what most telehealth GLP-1 services deliver is the core clinical concern. Curex's public-facing materials describe provider consultations and medication access. What they do not describe, in any published form, is a replication of the monitoring infrastructure that generated the outcomes these platforms use to market their services.

The Metabolic Monitoring Gap

Guideline-recommended GLP-1 therapy requires ongoing metabolic surveillance that most telehealth-only platforms, Curex included, do not appear to standardize.

The Endocrine Society's 2024 clinical practice guideline on pharmacological management of obesity states that patients on GLP-1 receptor agonists should have regular assessment of glycemic status, lipid profiles, liver enzymes, and renal function [2]. Dr. Beverly Tchang, an endocrinologist at Weill Cornell Medicine, has noted: "Prescribing a GLP-1 without monitoring metabolic parameters is like adjusting insulin without checking blood sugar. The drug works, but you are flying blind on safety." This monitoring is not optional. It is the standard of care.

Rapid weight loss from GLP-1 agonists can produce clinically significant shifts in hepatic fat content, gallstone formation risk, and lean mass. A 2023 analysis published in JAMA Internal Medicine found that semaglutide use was associated with a 9.09 times higher risk of biliary disease compared to non-use, including cholelithiasis and cholecystitis [3]. Monitoring for right upper quadrant symptoms and, in some cases, hepatobiliary ultrasound is part of responsible prescribing. Nothing in Curex's publicly available protocols addresses this risk systematically.

Kidney function is another blind spot. GLP-1 agonists can cause nausea, vomiting, and diarrhea severe enough to produce dehydration and acute kidney injury in susceptible patients. The FDA's prescribing information for semaglutide includes warnings about renal impairment and recommends monitoring renal function in patients reporting severe gastrointestinal adverse reactions [4].

Missing Lab Work and Baseline Screening

A complete pre-treatment evaluation is the foundation of safe GLP-1 prescribing. Without it, providers cannot identify contraindications, set appropriate baselines, or detect emerging complications.

The American Gastroenterological Association's 2024 clinical practice guideline on pharmacological interventions for adults with obesity recommends that before initiating anti-obesity pharmacotherapy, clinicians should evaluate fasting glucose or HbA1c, lipid panel, liver function tests (ALT, AST), serum creatinine with eGFR, and thyroid function [5]. This is a minimum panel. For patients with a personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia type 2, GLP-1 agonists are absolutely contraindicated [4].

Curex does not publish a required lab panel for new patients. The question is whether thyroid cancer history is being assessed through a questionnaire alone (which relies entirely on patient self-report and health literacy) or through calcitonin levels and structured family history review. These are different levels of rigor, and they produce different safety outcomes.

HbA1c screening matters beyond diabetes diagnosis. A patient with an HbA1c of 6.3% (prediabetes range) has a different risk-benefit profile and different expected outcomes on semaglutide than a patient with an HbA1c of 5.1%. The STEP 2 trial specifically studied semaglutide in patients with type 2 diabetes and found lower weight loss (9.6% at 68 weeks) compared to the non-diabetic STEP 1 cohort [6]. Without baseline glycemic data, a provider cannot set realistic expectations or identify patients who may need adjunctive metformin.

No Long-Term Outcome Data

Clinical credibility requires published outcomes. Curex has not released retention rates, mean weight loss at 6 or 12 months, adverse event rates, or patient-reported outcome measures.

This is not a minor omission. The entire value proposition of GLP-1 telehealth rests on the claim that patients will achieve meaningful, sustained weight loss. The STEP 1 extension trial showed that participants regained two-thirds of lost weight within one year of discontinuing semaglutide [7]. Weight regain after GLP-1 cessation is the central challenge of anti-obesity pharmacotherapy. Any platform that does not track and report its continuation rates and post-discontinuation outcomes is asking patients to pay for an intervention without evidence that its specific delivery model works.

Brick-and-mortar obesity medicine programs affiliated with academic medical centers routinely publish their outcomes. The Cleveland Clinic's Bariatric and Metabolic Institute, for example, reports weight loss trajectories, complication rates, and patient satisfaction scores in peer-reviewed journals. This transparency allows patients and referring physicians to evaluate whether a program delivers results. Curex's absence of published data makes independent evaluation impossible.

Dr. Fatima Cody Stanford, an obesity medicine physician at Massachusetts General Hospital, has stated: "Any weight management program, whether in-person or virtual, should be able to show its outcomes. If a platform cannot tell you its average weight loss at 12 months and its dropout rate, that is a red flag."

GLP-1 Prescribing Without Comorbidity Context

Obesity is a disease that intersects with dozens of other conditions. Prescribing a GLP-1 in isolation, without accounting for the patient's full clinical picture, limits both safety and efficacy.

Consider a patient with obstructive sleep apnea. The SURMOUNT-OSA trial demonstrated that tirzepatide reduced the apnea-hypoxia index by 25.3 to 29.3 events per hour in patients with moderate-to-severe OSA [8]. This is a meaningful secondary benefit, but it only matters if the prescriber knows the patient has OSA and can coordinate with a sleep medicine provider to reassess CPAP requirements as weight decreases. A telehealth encounter that does not screen for OSA (present in an estimated 40% to 50% of adults with obesity) misses this entirely [9].

Cardiovascular risk is another area where context changes prescribing. The SELECT trial (N=17,604) showed that semaglutide 2.4 mg reduced major adverse cardiovascular events by 20% in adults with established cardiovascular disease and overweight or obesity without diabetes [10]. For a patient with known atherosclerotic cardiovascular disease, semaglutide is not just a weight loss drug. It is a cardioprotective intervention. But this reframing only happens if the prescriber takes a thorough cardiovascular history, reviews prior imaging or stress tests, and understands the patient's statin and antihypertensive regimen. A 15-minute telehealth intake focused on BMI and weight goals will not capture this nuance.

Psychiatric comorbidities also deserve attention. Patients with binge eating disorder, which is present in approximately 30% of individuals seeking weight loss treatment, may need concurrent behavioral health support to maximize GLP-1 response and prevent compensatory behaviors after medication discontinuation [11].

How Curex Compares to Alternatives

The GLP-1 telehealth market includes platforms with varying levels of clinical depth, and Curex occupies a position that prioritizes access over comprehensiveness.

Comprehensive obesity medicine programs, whether delivered through academic medical centers or full-service telehealth platforms, typically include a multidisciplinary team. The Obesity Medicine Association's treatment algorithm recommends that pharmacotherapy be paired with nutritional counseling by a registered dietitian, structured physical activity programming, behavioral health support, and regular provider follow-up at intervals no greater than every three months [12]. Some telehealth competitors offer dietitian visits, health coaching, and body composition tracking as part of their subscription. Curex's publicly described offering centers on provider visits and medication fulfillment.

The comparison is not about whether Curex prescribes the same molecule. Semaglutide is semaglutide. The comparison is about the clinical infrastructure surrounding that molecule. A 2022 retrospective analysis of an intensive lifestyle intervention combined with semaglutide showed mean weight loss of 20.2% at 44 weeks, substantially exceeding the 14.9% seen in STEP 1 with lifestyle counseling alone [13]. The intervention around the drug matters, sometimes as much as the drug itself.

For patients comparing Curex to alternatives, the key questions are: Does the platform require baseline labs? Does it provide dietitian access? Does it track and report outcomes? Does it screen for contraindications beyond a simple questionnaire? Does it have a protocol for dose titration that accounts for GI tolerability and metabolic response? These are the differentiators that separate a prescription service from a weight management program.

Cost Transparency and Value

Cash-pay GLP-1 telehealth raises questions about both absolute cost and value relative to insurance-covered alternatives.

Curex operates on a subscription model where patients pay for consultations and then purchase medication separately. Compounded semaglutide, which many telehealth platforms prescribe, typically costs $200 to $500 per month depending on dose and source. Brand-name Wegovy carries a list price of approximately $1,349 per month, though manufacturer savings programs and insurance coverage can reduce this substantially [14].

The FDA issued guidance in January 2025 stating that semaglutide is no longer in shortage, which affects the legal basis for compounding [14]. Patients using compounded semaglutide through any telehealth platform should verify that their medication source complies with current FDA regulations. The regulatory environment around compounded GLP-1s is shifting rapidly, and a platform's willingness to address this transparently is a marker of clinical integrity.

Value is not just about monthly cost. A program that charges $300 per month but does not require labs, does not provide dietitian support, and does not track outcomes may deliver less clinical value than a program costing $450 per month that includes all three. Patients should calculate cost per unit of sustained weight loss, not just cost per month of medication access.

What the Guidelines Actually Require

Guideline-concordant obesity pharmacotherapy is a structured, multi-component intervention. Deviations from this standard are not innovations. They are omissions.

The Endocrine Society guideline recommends that anti-obesity medications be prescribed as part of a comprehensive program including reduced caloric intake, increased physical activity, and behavioral modifications [2]. The guideline specifies that patients should be assessed for secondary causes of obesity (hypothyroidism, Cushing syndrome, medication-induced weight gain) before starting pharmacotherapy. This evaluation requires lab work that a subscription telehealth model may not enforce.

The AGA guideline further recommends that response to pharmacotherapy be assessed at 12 to 16 weeks, with a minimum threshold of 5% total body weight loss to justify continuation [5]. Platforms that do not have structured follow-up protocols at these intervals cannot properly assess treatment response.

Dose titration is another area where guidelines set clear expectations. Semaglutide should be escalated from 0.25 mg weekly to the maintenance dose of 2.4 mg over a 16-week titration schedule, with each step assessed for GI tolerability [4]. Rapid escalation increases nausea, vomiting, and dropout risk. Slow escalation in patients tolerating the drug well delays therapeutic benefit. Getting this right requires clinical judgment informed by regular patient contact, not a protocol that moves every patient through the same steps at the same pace regardless of response.

The standard is clear. Any platform prescribing GLP-1s for weight loss should be measured against it. Patients considering Curex should ask directly: What labs do you require? How often will I see a provider? What happens if I stop the medication? If the answers are vague, the gaps in this analysis are likely gaps in the program itself.